Business ❯ Pharmaceutical Industry

Novo Nordisk

Drug Development Eli Lilly Market Competition Financial Performance Drug Sales Market Impact Product Launch Market Analysis Drug Pricing Market Strategies Market Performance Product Pricing Sales Stock Market Research and Development CEO Testimony Growth Driver Research Partnerships Eli Lilly and Co. Obesity Treatments Drug Pricing Agreements Market Dynamics Sales Growth Drug Manufacturing Corporate Executives Drug Pricing Strategies Pricing Strategies Product Supply Product Liability Company Strategy Drug Profits Product Integrity Manufacturing Constraints Wegovy U.S. Market Global Market Expansion Economic Impact Semaglutide Corporate Structure Corporate Leadership Market Trends Future Plans Market Launch Key Drugs Sales Performance Stock Performance Product Management Drug Production CEO Statements Market Practices Product Offerings Weight Loss Drugs Drug Prices Product Compliance Product Development CEO Meetings Employment

Novo Nordisk’s Wegovy Pill Shows Strong Results, Reinforcing Stock Rebound

New trial data suggests the weight-loss pill could sustain recent business gains.

White House Finalizes GLP-1 Price Deal With Lilly and Novo, Setting $50 Medicare Copays

U.S. Strikes Price-Cut Deals With Novo Nordisk and Eli Lilly for GLP‑1s, With Medicare Pilot in 2026

Sam’s Club Joins Costco in Offering $499 Wegovy and Ozempic

Costco Adds $499 Ozempic and Wegovy Offer Across U.S. Pharmacies

Costco to Offer Ozempic and Wegovy for $499 a Month to Self-Pay Members Nationwide

Novo Nordisk Freezes Hiring as Layoffs Loom in GLP-1 Retrenchment

FDA Ends GLP-1 Drug Shortages, Triggering New Pricing and Coverage Moves